COMPASS Pathways

About:

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression.

Website: https://compasspathways.com

Twitter/X: COMPASSPathway

Top Investors: Hercules Capital, RA Capital Management, Perceptive Advisors, Founders Fund, ATAI Life Sciences

Description:

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression. Compass Pathways conducts clinical trials and research to assess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression.

Total Funding Amount:

$271M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Altrincham, Cheshire, United Kingdom

Founded Date:

2016-06-13

Founders:

Ekaterina Malievskaia, George Goldsmith, Lars Christian Wilde

Number of Employees:

101-250

Last Funding Date:

2023-08-16

IPO Status:

Public

Industries:

© 2025 bioDAO.ai